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Resection of asymptomatic primary tumour in unresectable
stage IV colorectal cancer: time to move on from propensity
matched scores to randomized controlled trials
Colorectal cancer (CRC) remains a major global disease burden
with over 1.2 million new cases each year – about half of those
who get the disease will die within 5 years of diagnosis1. At the
time of diagnosis, some 20% already present with stage IV dis-
ease, of which only a minority (15-20%) are amenable for
attempt at curative resection (usually for liver metastasis),
either as an upfront combined resection or as a staged
approach with or without combinations of neoadjuvant sys-
temic treatment 2. Despite several improvements in systemic
therapy and modern surgical strategies for attempts at cure, the
majority of patients with stage IV disease are unresectable and
only amenable to palliative strategies. For patients who have a
symptomatic primary (e.g. obstruction, perforation or bleed-
ing) a surgical resection or stoma may be warranted if other
attempts at bypassing the problem or as a bridge to later sur-
gery is not possible (e.g. endoscopic stenting)3. In contrast, for
those patients with stage IV disease having an asymptomatic
primary tumour (either in colon or rectum) the role and poten-
tial benefit (if any) – and, notably, also the potential harm – of
resection of the primary tumour has been much more contro-
versial. Thus, the debate continues4–7.
Contestants against primary resection would argue that pal-
liation is not possible if the patient does not have any symp-
toms to “palliate” and the limiting factor for survival is control
of the metastatic disease and so systemic therapy should be pri-
oritized. Proponents for resection of the primary tumour argue
that reducing the tumour load reduces the disease burden and
even disease progress, makes systemic therapy more effective
and pre-emptively manages potential complications from
occurring. Both sides may be right – and wrong.
Indeed, a more aggressive approach to unresectable stage IV
disease was seen in the past, with every 3 in 4 patients having
the primary tumour resected, with a drop to just over every
one in two being resected in the latter time period8,9. Of notice,
as the resection rates have dropped, the survival rates doubled
from 8.6% in 1988 to 17.8% in 2009 (P<0.001)9. However,
using the same datasets, other investigators have come to dif-
ferent conclusions regarding resections of asymptomatic pri-
mary tumours in otherwise unresectable stage IV colorectal
cancer10. Notably, these cohort studies sampled over longer
time periods are biased towards the multiple factors that
changed with the time and development in diagnostics, man-
agement and available systemic treatment that have not been
controlled for in the comparative analyses.
In this issue of the Journal, a nationwide cohort study from
the Netherlands investigated survival after primary tumour
resection in unresectable stage IV CRC11. Using a propensity
score matched approach, they found a survival benefit for those
who underwent primary tumour resection (n52746) compared
to systemic chemotherapy (n53345). When matched by pro-
pensity scores in a 1:1 fashion, resection was beneficial for sur-
vival when combined with systemic therapy both before and
after resection, yet resection upfront with subsequent chemo-
therapy proved to be best. The authors conclude that this treat-
ment should be entertained more often as an option, even for
those with no symptoms from the primary tumour.
While the findings may truly be so that primary tumour
resection provides for a survival benefit, several points need
to be considered before jumping to conclusions. Notably,
propensity scores can be used in several ways12, of which
propensity score matching is one. This involves a matched
modelling of assembled pairs of two interventions (in this
case resection or no resection) to selected baseline character-
istics in an attempt to reduce bias. It works similar to a ran-
domized trial, except it is not randomized and it is not a
trial. Propensity score matching is still based on matching of
the available, chosen data for matching. In the current study,
a total of 1737 (28,5%) of the patients were not ‘matchable’
(one third resected primary, two thirds non-resected) and
thus excluded. As the authors matched pairs based on year of
diagnosis, age, tumour location, morphology and number of
organs with metastases (1 or >1), several factors that may
influence survival were not matched for. Notably, presence of
comorbidity (e.g. ASA score, Charlson-Deyo score, presence
of any organ function deficits etc) or functional status (e.g.
ECOG status level) were not available and thus not con-
trolled for. Also, TNM stage was not matchable due to the
nature of those non-resected (lacking a pTNM status). Thus,
it may still be so that those who received surgery up front
were deemed fitter and more likely to tolerate a surgical pro-
cedure. Or, alternatively, had less extensive disease overall.
Further, one needs to scrutinize the choice of endpoint in
the current setting of non-curable disease. When there are no
symptoms to alleviate, one may question if overall survival is
the best outcome measure to address. The added months of
survival may truly be valuable for the individual patient, but
one should consider at which risk and at what price this comes.
For one, the current study had a 30-day mortality rate in the
resected patients at 9%, which was similar for the systemic
therapy group. These numbers are staggering, and far beyond
those seen in any controlled trial of systemic therapy. However,
they may actually reflect the truth in a real-life setting and, also,
points to the risk of adversary effects of “just doing something” in
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for a very high perioperative mortality) were excluded, the rate of
short-term deaths in what should be considered ‘elective’ surgery
is considerable. For patients aged over 75 years, the 30-day mor-
tality rate was even higher at 15%. The message is that either ‘pal-
liative’ approach comes at a high risk of short-term death,
knowing that these patients were likely deemed better performers
than the ‘best supportive care’ candidates that were not included
in the analyses. So, with a high risk of death (one in ten) for a rela-
tively short survival benefit (of a few months) in otherwise
asymptomatic patients, one may question if overall survival is the
correct endpoint to consider. Further, doing landmark analysis of
survivors beyond a 6months period (during which time a consid-
erable number of patients die) further skews the data towards
favourable reporting of survivor bias (you have to be alive in
order to live longer). Further, perioperative risk for anastomotic
leaks is higher in patients withmetastatic disease13, and this again
strongly influences survival14.
Arguably, quality of life may be far more important in this
patient group, whose longevity is limited but for whom symp-
tom control is paramount. Data on QoL are very limited but
may improve with surgical resection, as demonstrated in a very
small (n524), uncontrolled, cohort study15. No other studies
have reported QoL data in this setting thus far16, which only
testifies to the glaring lack of research in this field17.
Several systematic reviews have been conducted16,18,19. Based
on limited data from few and heterogeneous studies with con-
siderable reported bias, the median survival is reported at 15.2
months (range 10-30.7 months) in the resection group and 11.4
months (range 3-22 months) in the non-resection group, with a
notable overlap in the reported ranges for both. This likely
reflects the poor selection of appropriate candidates and a huge
case-mix in disease burden, functional status and additional
comorbidity. Also, a number of previously reported propensity
matched studies have shown a variation in patient selection and
outcomes10,20–25, but presents a reserved but favourable view on
primary tumour resection for selected patients. As evidenced
from one recent metaanalysis of heterogeneous studies, the
patients that may benefit most from primary tumour resection
are those who are young, fit, have a good performance status,
and have minimal systemic disease19. However, the propensity
matched cohort and their associated findings have reached a
limit in terms of information for decision-making. It is now
time to move on to randomized trials.
Indeed, a lack of randomized controlled trials (RCTs) in
this area is what keeps the debate alive. Thus, several ongo-
ing randomized trials (the German-Austrian SYNCHRO-
NOUS26 trial, the Dutch-Danish CAIRO427 trial, the Korean
multicenter trial28, and the Chinese trial29) and their
expected results are much needed (Table 1). In addition to
survival outcomes, at least three of the RCTs have stated
QoL as secondary outcomes, and as such these measures will
be of additional value for decision-making for both patients
and caregivers alike.
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Table 1. Overview of ongoing randomized controlled trials for resection of primary tumour in unresectable stage IV colon or rectal cancer.
Trial/name Origin Trial3 Inclusion age Primary outcome
sample
(n) Est. Completed, date
SYNCRONOUS Germany, Austria ISRCTN30964555 18 years1 OS, 3 yrs 800 July 2019
CAIRO4 Netherlands, Denmark NCT01606098 18 years OS, 5 yrs 360 August 2020
CCRe-IV Spain NCT02015923 18 years OS, 2 yrs 336 November 2016
Korean multicenter Korea NCT01978249 20-90 yrs2 OS, 2 yrs 480 April 2018
China multicenter China NCT02149784 18-75 years OS, 3 yrs 480 July 2019
1for colon cancer primary only; rectal cancers are excluded
2colon and upper rectum cancers
3from either registry ISRCTN (www.isrctn.com) or NCT (www.Clinicaltrials.gov).







Int. J. Cancer: 139, 1927–1929 (2016) VC 2016 The Authors International Journal of Cancer published by John Wiley & Sons Ltd on behalf of
Union for International Cancer Control
References
1. Brenner H, Kloor M, Pox CP. Colorectal cancer.
Lancet (London, England). 2014;383(9927):
1490–1502.
2. Adam R, de Gramont A, Figueras J, et al. Manag-
ing synchronous liver metastases from colorectal
cancer: a multidisciplinary international consen-
sus. Cancer treatment reviews. 2015;41(9):
729–741.
3. Søreide K. Emergency management of acute
obstructed left-sided colon cancer: loops, stents
or tubes? Endoscopy. 2013;45(4):247–248.
4. Patel S, Chang GJ. Primary Tumor Resection in
Metastatic Colorectal Cancer: Please Pass the Salt.
JAMA oncology. 2015;1(9):1213–1214.
5. Chang GJ. Primary tumor resection in stage IV
colorectal cancer: the debate continues. Diseases
of the colon and rectum. 2011;54(8):919–920.
6. Mik M, Dziki L, Galbfach P, Trzcinski R, Sygut
A, Dziki A. Resection of the primary tumour or
other palliative procedures in incurable stage IV
colorectal cancer patients? Colorectal disease: the
official journal of the Association of Coloproctol-
ogy of Great Britain and Ireland. 2010;12(7
Online):e61–67.
7. Cellini C, Hunt SR, Fleshman JW, Birnbaum EH,
Bierhals AJ, Mutch MG. Stage IV rectal cancer
with liver metastases: is there a benefit to resec-
tion of the primary tumor? World journal of sur-
gery. 2010;34(5):1102–1108.
8. Shapiro M, Rashid NU, Whang EE, et al. Trends
and predictors of resection of the primary tumor
for patients with stage IV colorectal cancer. Jour-
nal of surgical oncology. 2015;111(7):911–916.
9. Hu CY, Bailey CE, You YN, et al. Time trend
analysis of primary tumor resection for stage IV
colorectal cancer: less surgery, improved survival.
JAMA surgery. 2015;150(3):245–251.
10. Tarantino I, Warschkow R, Worni M, et al. Prog-
nostic Relevance of Palliative Primary Tumor
Removal in 37,793 Metastatic Colorectal Cancer
Patients: A Population-Based, Propensity Score-
Adjusted Trend Analysis. Annals of surgery. 2015;
262(1):112–120.
11. ’t Lam-Boer J, Van der Geest L, Verhoef C,
Elferink M, Koopman M, de Wilt J. Palliative
resection of the primary tumor is associated with
improved overall survival in incurable stage IV
colorectal cancer: a nationwide population-based
propensity-score adjusted study in The Nether-
lands. Int J Cancer. 2016;in press:in press.
12. Haukoos JS, Lewis RJ. The Propensity Score.
Jama. 2015;314(15):1637–1638.
13. Kaser SA, Mattiello D, Maurer CA. Distant
Metastasis in Colorectal Cancer is a Risk Factor
for Anastomotic Leakage. Annals of surgical
oncology. 2016;23(3):888–893.
14. Smith JD, Butte JM, Weiser MR, et al. Anasto-
motic leak following low anterior resection in
stage IV rectal cancer is associated with poor sur-
vival. Annals of surgical oncology. 2013;20(8):
2641–2646.
15. Tan WJ, Chew MH, Tan IB, et al. Palliative sur-
gical intervention in metastatic colorectal carcino-
ma: a prospective analysis of quality of life.
Colorectal disease: the official journal of the Asso-
ciation of Coloproctology of Great Britain and Ire-
land. 2016;18(4):357–363.
16. Ahmed S, Shahid RK, Leis A, et al. Should non-
curative resection of the primary tumour be per-
formed in patients with stage iv colorectal
cancer? A systematic review and meta-analysis.
Current oncology (Toronto, Ont.). 2013;20(5):
e420–441.
17. Søreide K, Søreide AH. Using patient-reported
outcome measures for improved decision-making
in patients with gastrointestinal cancer - the last
clinical frontier in surgical oncology? Frontiers in
oncology. 2013;3:157.
18. Cirocchi R, Trastulli S, Abraha I, et al. Non-
resection versus resection for an asymptomatic
primary tumour in patients with unresectable
stage IV colorectal cancer. The Cochrane database
of systematic reviews. 2012;8:Cd008997.
19. Clancy C, Burke JP, Barry M, Kalady MF, Calvin
Coffey J. A meta-analysis to determine the effect
of primary tumor resection for stage IV colorectal
cancer with unresectable metastases on patient
survival. Annals of surgical oncology. 2014;21(12):
3900–3908.
20. Gulack BC, Nussbaum DP, Keenan JE, et al. Sur-
gical Resection of the Primary Tumor in Stage IV
Colorectal Cancer Without Metastasectomy Is
Associated With Improved Overall Survival Com-
pared With Chemotherapy/Radiation Therapy
Alone. Diseases of the colon and rectum. 2016;
59(4):299–305.
21. Ishihara S, Hayama T, Yamada H, et al. Prognos-
tic impact of primary tumor resection and lymph
node dissection in stage IV colorectal cancer with
unresectable metastasis: a propensity score analy-
sis in a multicenter retrospective study. Annals of
surgical oncology. 2014;21(9):2949–2955.
22. Karoui M, Roudot-Thoraval F, Mesli F, et al. Pri-
mary colectomy in patients with stage IV colon
cancer and unresectable distant metastases
improves overall survival: results of a multicentric
study. Diseases of the colon and rectum. 2011;
54(8):930–938.
23. Yun JA, Huh JW, Park YA, et al. The role of pal-
liative resection for asymptomatic primary tumor
in patients with unresectable stage IV colorectal
cancer. Diseases of the colon and rectum. 2014;
57(9):1049–1058.
24. Ishihara S, Nishikawa T, Tanaka T, et al. Benefit
of primary tumor resection in stage IV colorectal
cancer with unresectable metastasis: a multicenter
retrospective study using a propensity score anal-
ysis. International journal of colorectal disease.
2015;30(6):807–812.
25. Ishihara S, Nishikawa T, Tanaka T, et al. Prog-
nostic impact of tumor location in stage IV colon
cancer: a propensity score analysis in a multicen-
ter study. International journal of surgery (Lon-
don, England). 2014;12(9):925–930.
26. Rahbari NN, Lordick F, Fink C, et al. Resection
of the primary tumour versus no resection prior
to systemic therapy in patients with colon cancer
and synchronous unresectable metastases (UICC
stage IV): SYNCHRONOUS–a randomised con-
trolled multicentre trial (ISRCTN30964555). BMC
cancer. 2012;12:142.
27. t Lam-Boer J, Mol L, Verhoef C, et al. The CAI-
RO4 study: the role of surgery of the primary
tumour with few or absent symptoms in patients
with synchronous unresectable metastases of
colorectal cancer–a randomized phase III study of
the Dutch Colorectal Cancer Group (DCCG).
BMC cancer. 2014;14:741.
28. Kim CW, Baek JH, Choi GS, et al. The role of
primary tumor resection in colorectal cancer
patients with asymptomatic, synchronous unre-
sectable metastasis: Study protocol for a random-
ized controlled trial. Trials. 2016;17:34.
29. Chen G. Palliative Resection of Asymptomatic
Primary Tumor Following Effective Induction
Chemotherapy in Colorectal Cancer Patients
With Unresectable Distant Metastasis: a Multi-
center, Prospective, Randomized Controlled
Study. 2014; https://clinicaltrials.gov/ct2/show/
study/NCT02149784?term5NCT02149







Int. J. Cancer: 139, 1927–1929 (2016) VC 2016 The Authors International Journal of Cancer published by John Wiley & Sons Ltd on behalf of
Union for International Cancer Control
